Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-181 in Phenylketonuria
NCT07241234Phase 1Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of AG-181 in phenylketonuria (PKU) (2 cohorts), sponsored by Agios Pharmaceuticals. Primary endpoint: Number of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to the Study Drug at 42 days. Started Apr 2026; status: recruiting.
02
Drugs
AG-181
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07241234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241234.